Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Dec;21(6):444-6.

[Effect of local immunotherapy of interleukin 2(IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas]

[Article in Chinese]
Affiliations
  • PMID: 14732977
Clinical Trial

[Effect of local immunotherapy of interleukin 2(IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas]

[Article in Chinese]
Enyi Tang et al. Hua Xi Kou Qiang Yi Xue Za Zhi. 2003 Dec.

Abstract

Objective: To evaluate the effect of locoregional immunotherapy of interleukin 2 (IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas.

Methods: Thirty-four patients with stage T3 or T4 oral squamous cell carcinoma were randomly divided into two groups, and treated with two therapies. 23 cases of them received immunochemotherapy and 11 cases received PVP chemotherapy. Changes of T lymphocyte subsets and B cells at tumor site in the two groups were compared before and after therapy.

Results: The relative numbers of CD4+, CD8+, CD20+ before and after treatment in immunochemotherapy were respectively 36.96, 35.65, 28.65 and 56.61, 38.52, 38.70. The numbers of CD4+, CD20+ increased significantly after immunochemotherapy. However, in chemotherapy group, there was no significant difference in numbers of CD4+, CD8+ and CD20+ cells between pre and post treatment.

Conclusion: Immunochemotherapy for oral squamous cell carcinomas may play an important role in increasing local immunity.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources